In vitro cytotoxicity of recombinant ricin A chain-antitransferrin receptor immunotoxin against human adenocarcinomas of the colon and pancreas.

The sensitivity of three human colon adenocarcinoma cell lines (LoVo, LS174T, and SW1116) and a human pancreatic adenocarcinoma cell line (Hs766T) to a recombinant ricin A chain-antitransferrin receptor immunotoxin was studied. In addition, the carboxylic ionophore monensin was used in conjunction with the immunotoxin to determine the possibility of increased cytotoxicity without loss of specificity. The immunotoxin, 454A12-rRTA, is composed of the monoclonal antibody 454A12 directed against transferrin receptor and of ricin A chain, which was produced by recombinant DNA techniques. In 18 h dose-response cytotoxicity assays, the median inhibitory dose (ID50) against LoVo, LS174T, and SW1116 was found to be 3 X 10(-10), 3.6 X 10(-11), and 3.6 X 10(-10) M, respectively; in the same assay, the ID50 for Hs766T was found to be 4 X 10(-10) M. In the presence of monensin, the ID50 for the adenocarcinoma cell lines was reduced 9-fold, 28-fold, and 5-fold, respectively. In cytotoxic kinetic assays, 50% of control protein inhibition was reached in immunotoxin-treated LS174T cells 12-fold faster in the presence of monensin than in its absence. Immunotoxin-treated LoVo cells reached 50% inhibition of control protein synthesis fivefold faster in the presence of monensin than in its absence. Furthermore, no toxicity of immunotoxin or potentiation by monensin was observed in either a control cell line (Swiss albino mouse 3T6) treated with specific immunotoxin or with a control immunotoxin assay. These results show the in vitro specificity and selectivity of 454A12-rRTA immunotoxin for human gastrointestinal and pancreatic cancer cell lines.

Enhancement of the specific cytotoxicity of a breast cancer-associated antigen immunotoxin by the carboxylic ionophore monensin.

Monensin is a carboxylic ionophore which dissipates proton gradients across cell membranes. Monensin is known to potentiate the cytotoxic activity of immunotoxins (antibody-toxin conjugates) directed against several human tumor-associated antigens. We have investigated the effect of monensin on an immunotoxin cytotoxic to the human breast cancer cell line MCF-7. This immunotoxin is composed of an antibody directed against a human breast cancer membrane antigen, and ricin A chain, which has been produced by recombinant DNA techniques. In a 16-hour cytotoxicity assay, monensin reduced 34-fold the median inhibitory dose, from 1.4 X 10(-8)M (without monensin) to 4.1 X 10(-10)M (with monensin). In timed cytotoxicity assays, 50% of control protein synthesis was reached in immunotoxin treated cells 8-fold faster in the presence of monensin (0.5 hours) than in its absence (4 hours). Monensin produced no enhancement of immunotoxin effect on a control cell line, nor on a control immunotoxin on MCF-7 cells, demonstrating specificity of monensin effect. In addition, specific immunotoxin alone or with monensin produced no toxicity on MCF-7 cells maintained at 23 degrees C. These results suggest that both binding and internalization of immunotoxin are necessary for the monensin effect. Monensin was a potent enhancer of immunotoxin effect on human breast cancer cells. This effect occurs without the presence of ricin B chain in the conjugate.